Financial Survey: Zura Bio (NASDAQ:ZURA) and PharmaCyte Biotech (OTCMKTS:PMCBD)

PharmaCyte Biotech (OTCMKTS:PMCBDGet Free Report) and Zura Bio (NASDAQ:ZURAGet Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

Institutional & Insider Ownership

0.0% of PharmaCyte Biotech shares are held by institutional investors. Comparatively, 61.1% of Zura Bio shares are held by institutional investors. 15.8% of Zura Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares PharmaCyte Biotech and Zura Bio’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
PharmaCyte Biotech N/A N/A -$3.83 million N/A N/A
Zura Bio N/A N/A -$69.24 million N/A N/A

Profitability

This table compares PharmaCyte Biotech and Zura Bio’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
PharmaCyte Biotech N/A -49.09% -43.39%
Zura Bio N/A -28.83% -22.91%

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for PharmaCyte Biotech and Zura Bio, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PharmaCyte Biotech 0 0 0 0 N/A
Zura Bio 0 1 4 0 2.80

Zura Bio has a consensus target price of $15.50, suggesting a potential upside of 369.70%. Given Zura Bio’s higher possible upside, analysts clearly believe Zura Bio is more favorable than PharmaCyte Biotech.

Volatility & Risk

PharmaCyte Biotech has a beta of 0.27, suggesting that its stock price is 73% less volatile than the S&P 500. Comparatively, Zura Bio has a beta of 0.16, suggesting that its stock price is 84% less volatile than the S&P 500.

Summary

Zura Bio beats PharmaCyte Biotech on 6 of the 8 factors compared between the two stocks.

About PharmaCyte Biotech

(Get Free Report)

PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes. The company was founded on October 28, 1996 and is headquartered in Laguna Hills, CA.

About Zura Bio

(Get Free Report)

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.

Receive News & Ratings for PharmaCyte Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharmaCyte Biotech and related companies with MarketBeat.com's FREE daily email newsletter.